Business
Jaguar Health Launches Website for Napo EU
Site contains links to information about post-COVID-19 ‘long-hauler' syndromeAn article published yesterday in the San Francisco Chronicle references diarrhea
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Site contains links to information about post-COVID-19 ‘long-hauler' syndromeAn article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the type of inflammation associated with HIV may also be present in long-hauler patientsNapo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in long-hauler COVID-19 recovery patients in EuropeSAN FRANCISCO, CA / ACCESSWIRE / February 23, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that the Company has launched the website for Napo EU, the anticipated subsidiary of the Company in Italy. Click here to visit the website.The Resources page of the site contains links to an assortment of third-party information about post-COVID long-hauler syndrome, as well as the challenges posed in Europe and elsewhere by vaccine distribution programs, vaccine skepticism, and the appearance of more transmissible mutated strains of SARS-CoV-2, the virus that causes COVID-19.\"Long-hauler syndrome has been generating a great deal of coverage over the past several months in major media around the globe,\" stated Lisa Conte, Jaguar's founder, president, and CEO. \"In fact, yesterday an article titled \"Terrifying 'post-COVID syndrome' is next focus for researchers in Bay Area and beyond\" was published by the San Francisco Chronicle. The article references diarrhea as a symptom of long-hauler syndrome, and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients. We believe that GI symptoms in long-hauler patients may be related to inflammation, and thus analogous to GI symptoms observed in people who have lived with HIV/AIDS for a long period of time.\"Gut inflammation referred to as enteropathy is a chronic syndrome that has been observed in people who live with HIV/AIDS for long periods of time and is manifested as chronic diarrhea. Crofelemer (Mytesi®), Napo's commercialized antidiarrheal drug, is FDA-approved in the U.S. for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.This past Friday, as also reported in the above-referenced the San Francisco Chronicle article, a University of Washington study published in the Journal of th...